ArticleMicrobiology spectrum2025
Six-year retrospective analysis of the epidemiology and risk factors of multidrug-resistant bloodstream infections in oncology patients in Jiangxi, China.
Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Bacterial profile, antimicrobial resistance patterns and associated factors among cancer patients at Hawassa University Comprehensive Specialized Hospital, Sidama region, Southern Ethiopia.BMC infectious diseases · 2026Article
- A comprehensive analysis of the kinetics of infection of lytic bacteriophages specific to the ESKAPE and critical pathogens.World journal of microbiology & biotechnology · 2026Review
- Investigation of pathogen resistance in Chinese cancer patients based on bacterial resistance surveillance in 23 provinces, 2016-2023.Frontiers in microbiology · 2026Article
- The Evolving Triad of Carbapenem Resistance: Emergence of Dominant CRPA, Persistent CRAB, and Rebounding CRKP in a Chinese Regional Hospital (2020-2024).Infection and drug resistance · 2026Article
- Pathogen spectrum and management strategies for opportunistic infections in lung cancer in the immunotherapy era: recent advances from fungi to mycobacteria.American journal of cancer research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer patients are particularly vulnerable to bloodstream infections (BSIs) due to their immunocompromised status. This retrospective study at Jiangxi Cancer Hospital (2019 to 2024) analyzed the bacterial spectrum, risk factors, and antimicrobial susceptibility profiles of BSIs in cancer patients. Logistic regression analysis was performed to identify risk factors associated with multidrug resistance (MDR) in Gram-positive and Gram-negative infections. A total of 1,161 bacteria were isolated from 954 oncological patients in 1,095 BSI episodes. Among these, 62.79% were Gram-negative bacteria, with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.